Magnoloside A

CAS : 113557-95-2

Ref. 3D-NEA55795

Informations sur le produit

• Nom: Magnoloside A
• Synonymes: b-D-Allopyranoside, 2-(3,4-dihydroxyphenyl)ethyl2-O-(6-deoxy-a-L-mannopyranosyl)-,3-[3-(3,4-dihydroxyphenyl)-2-propenoate], (E)-, β-<span class="text-smallcaps">D</smallcap>-Allopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 2-O-(6-deoxy-α-<smallcap>L</span>-mannopyranosyl)-, 3-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate], β-<span class="text-smallcaps">D</smallcap>-Allopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 2-O-(6-deoxy-α-<smallcap>L</span>-mannopyranosyl)-, 3-[3-(3,4-dihydroxyphenyl)-2-propenoate], (E)-, β-D-Allopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 2-O-(6-deoxy-α-L-mannopyranosyl)-, 3-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate], β-D-Allopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 2-O-(6-deoxy-α-L-mannopyranosyl)-, 3-[3-(3,4-dihydroxyphenyl)-2-propenoate], (E)-

Description

Magnoloside A is a phenolic compound that has been shown to have immunomodulatory effects in the treatment of cryptococcal meningitis. Magnoloside A was found to be effective against Cryptococcus neoformans, with a MIC of 0.5 mg/mL, and had no cytotoxic effects on human cells at concentrations up to 2 mg/mL. The drug was also found not to be toxic in rats at doses up to 10 g/kg. Magnoloside A has been shown to have a high bioavailability when given orally, as well as an excellent pharmacokinetic profile. It is metabolized by fatty acid oxidation and conjugation with glucuronic acid, making it suitable for oral administration. This drug can be detected using liquid chromatography-mass spectrometry (LC-MS) and is characterized by its chromatographic behavior.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 624.6 g/mol
• Formule: C₂₉H₃₆O₁₅
• Degré de pureté: Min. 95%